AcelRx Pharmaceuticals Inc. (ACRX) Drops 8.72% on January 13

Equities Staff |

AcelRx Pharmaceuticals Inc. (ACRX) was one of the Russell 2000's biggest losers for Wednesday January 13 as the stock slid 8.72% to $2.93, a loss of $-0.28 per share. Starting at an opening price of $3.25 a share, the stock traded between $2.90 and $3.29 over the course of the trading day. Volume was 337,840 shares over 1,387 trades, against an average daily volume of 571,956 shares and a total float of 44.45 million.

The losses send AcelRx Pharmaceuticals Inc. down to a market cap of $130.22 million. In the last year, AcelRx Pharmaceuticals Inc. has traded between $9.32 and $2.92, and its 50-day SMA is currently $4.53 and 200-day SMA is $4.08.

AcelRx Pharmaceuticals Inc is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of therapies for the treatment of acute pain.

AcelRx Pharmaceuticals Inc. is based out of Redwood City, CA and has some 32 employees. Its CEO is Howard Rosen.

For a complete fundamental analysis analysis of AcelRx Pharmaceuticals Inc., check out Equities.com’s Stock Valuation Analysis report for ACRX. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

CMX Gold & Silver Corp.

CMX Gold & Silver Corp is an exploration stage company. The Company is engaged in the acquisition, exploration and development of silver and copper/gold properties in the USA.

Private Markets

MyForce, Inc.

As parents, we constantly worry about the safety of our loved ones. The media bombards us with incidents from across the nation school shootings, frequent assaults on campuses, and crimes…

BioSculpture Technology, Inc.

BioSculpture Technology, Inc. (“BST”) is a commercial-stage medical device manufacturer of liposuction surgical instruments for surgeons. It offers the FDA-cleared Twin Cannula Assisted Liposuction ("TCAL") Airbrush Liposculptor II® controllers, Airbrush®…